Jim Cramer Gives His Opinion On Merck And Smith & Wesson

On CNBC's Mad Money, Jim Cramer spoke about Merck & Co., Inc. MRK. He thinks that the stock would be trading around $65 or $66 on the good news about its drug Keytruda, if there were no political worries. If it doesn't get contested after the election, the stock is going to trade higher, thinks Cramer.

Smith & Wesson Holding Corp SWHC is a good company and there are no laws in the US that would negatively impact its performance, thinks Cramer. He sees a decent value in the stock.